Lunai Bioworks raises $20M to expand CNS drug delivery tech for Alzheimer's and neurological therapies.

Lunai Bioworks completed a $20 million preferred equity issuance to acquire intellectual property that enhances its central nervous system (CNS) platform with new drug delivery technologies targeting the blood-brain barrier. This acquisition supports Alzheimer's and other neurological disease treatments by enabling therapies to better reach the brain, including nose-to-brain and BBB-crossing delivery methods. The expanded platform also facilitates combination therapies, aligns with AI-driven patient stratification, and opens regulatory and partnership opportunities. This move strengthens Lunai's position in CNS drug development and biodefense applications, aiming for more effective and targeted treatments.